Literature DB >> 10609769

Acute myocardial infarction following gemcitabine therapy--a case report.

T Kalapura1, M Krishnamurthy, C V Reddy.   

Abstract

The authors report a case of acute myocardial infarction following gemcitabine infusion and electrocardiographic abnormalities suggestive of ischemia on rechallenge of the drug. The possible underlying mechanisms of ischemia and/or infarction and the strategies for prevention are discussed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10609769     DOI： 10.1177/000331979905001208

Source DB:  PubMed          Journal:  Angiology        ISSN： 0003-3197            Impact factor:   3.619


  6 in total

Review 1.  Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Feng Lin; Yuan-Jue Sun; Li-Na Tang; Zan Shen; Yang Yao
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

2.  Acute coronary stent thrombosis in cancer patients: a case series report.

Authors:  Joo Myung Lee; Chang-Hwan Yoon
Journal:  Korean Circ J       Date:  2012-07-26       Impact factor: 3.243

Review 3.  Gemcitabine-induced cardiomyopathy: a case report and review of the literature.

Authors:  Muhammad F Khan; Silvija Gottesman; Ravichandra Boyella; Elizabeth Juneman
Journal:  J Med Case Rep       Date:  2014-06-23

4.  Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity.

Authors:  Donya Mohebali; Jason Matos; James Ducksoon Chang
Journal:  ESC Heart Fail       Date:  2016-09-21

Review 5.  Myocardial Ischemia Related to Common Cancer Therapy-Prevention Insights.

Authors:  Minerva Codruta Badescu; Oana Viola Badulescu; Dragos Viorel Scripcariu; Lăcrămioara Ionela Butnariu; Iris Bararu-Bojan; Diana Popescu; Manuela Ciocoiu; Eusebiu Vlad Gorduza; Irina Iuliana Costache; Elena Rezus; Ciprian Rezus
Journal:  Life (Basel)       Date:  2022-07-12

Review 6.  Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences.

Authors:  Stefan A Lange; Holger Reinecke
Journal:  Cancers (Basel)       Date:  2022-01-16       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.